Doris Peterkin specializes in solving the operational and organizational challenges facing clinical and commercial stage clients in small to mid-size life science companies, including start-ups and companies who are leveraging “virtual” operational models. In addition to providing strategic assessments, Doris serves in interim C-level role (CEO, COO) for those clients in the process of building their executive teams. She has led translation of new therapies from preclinical development into early clinical trials and has extensive experience working with clinical key opinion leaders in oncology. Her technology expertise includes biologics, cell-based therapeutics and combination medical devices.
Over her career, Doris has served in senior roles in corporate development, marketing, program management and product development including Genzyme and Antigenics (now Agenus). Most recently, Doris was the CEO of OncoPep, a clinical stage biotech developing immunotherapeutics for the treatment of hematologic and solid tumors. Prior to OncoPep, Doris was CEO of Healagenics, (biologic solutions for wound care) and co-founded MIACH Orthopaedics (bioengineered surgical implants for connective tissue restoration).
Doris is a mentor with the MIT Venture Mentoring Service and an advisor with Springboard Enterprises.
Doris has an MBA from Boston University School of Management and a B.S. in biochemistry from VA TECH.